
Opinion|Videos|January 31, 2025
Patient Selection for Aflibercept 8 mg
Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Who is the ideal patient for aflibercept 8 mg?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Clinical Trials at the Summit 2026: First-time data, AI, and the next generation of retinal treatments
2
The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS
3
Geographic atrophy: When lesion borders cannot be graded
4
FDA guidance to help accelerate cell and gene therapies
5





















